A View from Industry

Pharmacoepidemiology, Fourth Edition

Volumn , Issue , 2007, Pages 77-101

  Reynolds, Robert F ^a   Glasser, Dale B ^a   Dieck, Gretchen S ^a  

^a PFIZER INC   (United States)

Author keywords

Epidemiologic design and industry methods; Epidemiology role in risk management; Long latency outcomes; PDUFA III legislation in pharmacoepidemiology; Pharmacogenomics; Portfolio planning and development; Post approval safety studies; Risk management regulatory and industry focus; Signal detection

Indexed keywords

EID: 33750448858     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470059876.ch7     Document Type: Chapter

References (162)

1. Vuckovic N, Nichter M. Changing patterns of pharmaceutical practice in the United States. Soc Sci Med 1997; 44: 1285-1302.
2. Kaitin KI, Manocchia M, Seibring M, Lasagna L. The new drug approvals of 1990, 1991, and 1992: trends in drug development. J Clin Pharmacol 1994; 34: 120-7.
3. Kaitin KI, Manocchia M. The new drug approvals of 1993, 1994, and 1995: trends in drug development. Am J Therapeutics 1997; 4: 46-54.
4. Kaitin KI, Healy EM. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Inf J 2000; 34: 1-14.
5. Kaitin KI, Cairns C. The new drug approvals of 1999, 2000, and 2001: Drug development trends a decade after passage of the Prescription Drug User Fee Act of 1992. Drug Inf J 2003; 37: 357-71.
6. Kermani F, Bonacossa P. Patent issues and future trends in drug development. J Comm Biotechnol 2003; 9: 332-8.
7. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2003. Washington DC: PhRMA; 2003.
8. Drews J. In Quest of Tomorrow's Medicines. New York: Springer; 1999.
9. Food and Drug Administration. Report to Congress: Report on Postmarketing Studies. Washington DC: FDAMA 130; US FDA.
10. Food and Drug Administration. From Test Tube to Patient: Improving Health Through Human Drugs. Washington DC: US FDA CDER; 1999.
11. Food and Drug Administration. Managing the Risk from Medical Product Use: Creating a Risk Management Framework. Washington DC: US FDA; 1999.
12. Hyslop DL, Read HA, Masica DN, Kotsanos JG. Pharmaceutical risk management: a call to arms for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 2002; 11: 417-20.
13. Andrews E, Dombeck M. The role of scientific evidence of risk and benefits in determining risk management policies for medications. Pharmacoepidemiology Drug Saf. In press.
14. Perfetto EM, Ellison R, Ackermann S, Sherr M, Zaugg AM. Evidence-based risk management: how can we succeed? Drug Inf J 2003; 37: 127-34.
15. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 335: 609-16.
16. Faich GA, Lawson DH, Tilson HH Walker AMl. Clinical trials are not enough: drug development and pharmacoepidemiology. J Clin Res Drug Dev 1987; 1: 75-8.
17. Rogers AS. Adverse drug events: identification and attribution. Drug Intell Clin Pharm 1987; 21: 915-20.
18. Food and Drug Administration. Roche laboratories announces withdrawal of Posicor from the market. FDA Talk Paper, June 8, 1998.
19. Andrade SE, Walker AM, Gottlieb LK, Hollenberg NK, Testa MA, Saperia GM et al. Discontinuation of antihyperlipidemic drugs-do rates reported in clinical trials reflect rates in primary care settings? NEJM 1995; 332: 1125-31.
20. Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther 1998; 20: C40-4.
21. Edwards IR, Olsson S. WHO Programme-Global Monitoring. In: Mann R, Andrews E, eds., Pharmacovigilance. New York: Wiley; 2002. p. 169-82.
22. Davis S, Raine JM. Spontaneous Reporting-UK. In: Mann R, Andrews E, eds., Pharmacovigilance. New York: Wiley; 2002. p. 195-208.
23. Moore N, Kreft-Jais C, Dahnani A. Spontaneous Reporting-France. In: Mann R, Andrews E, eds., Pharmacovigilance. New York: Wiley; 2002. p. 209-18.
24. Graham DJ, Ahmad SR, Piazza-Hepp T. Spontaneous Reporting-USA. In: Mann R, Andrews E, eds., Pharmacovigilance. New York: Wiley; 2002. p. 219-28.
25. Moride Y, Haramburu F, Requejo AA, Begaud B. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997; 43: 177-81.
26. Alvarez-Requejo A, Carvajal A, Begaud B, Moride Y, Vega T, Martin Arias LH. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54: 483-8.
27. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA 1999; 281: 824-9.
28. Lasagna L. The Halcion story: trial by media. Lancet 1980; 1: 815-6.
29. Rossi AC, Hsu JP, Faich GA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. BMJ 1987; 294: 147-50.
30. Meinzinger MM, Barry WS. Prospective study of the influence of media on reporting medical events. Drug Inf J 1990; 24: 575-7.
31. Teicher MH, Glod C, Cole J. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207-10.
32. Ahmad SR. USA: Fluoxetine "not linked to suicide". Lancet 1991; 338: 875-6.
33. FDA Psychopharmacologic Drugs Advisory Committee Meeting. September 21, 1991.
34. Heiligenstein JH, Beasley CM Jr, Potvin JH. Fluoxetine not associated with increased aggression in controlled clinical trials. Int Clin Psychopharmacol 1993; 8: 277-80.
35. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjects. Arch Gen Psych 1997; 54: 1081-8.
36. Warshaw MG. Keller MB. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psych 1996; 57: 158-66.
37. Leon AC, Keller MB, Warshaw MG, Mueller TI, Solomon DA, Coryell W, Endicott J. Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am J Psych 1999; 156: 195-201.
38. Finch RG. The withdrawal of Temafloxacin: are there implications for other quinolones? Drug Saf 1993; 8: 9-11.
39. Clark JA, Klincewicz SL, Stang PE. Spontaneous adverse event signaling methods: classification and use with health care treatment products. Epidemiol Rev 2001; 23: 191-210.
40. Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2003; 37.
41. Evans SJW, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-6.
42. Moore N, Hall G, Sturkenboom M, Mann R, Lagnaoui R, Begaud B. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole. Pharmacoepidemiol Drug Saf 2003; 12: 271-81.
43. Edwards RI, Lindquist M, Bate A. Data Mining. In: Mann R, Andrews E, eds., Pharmacovigilance. New York: Wiley; 2002. p. 291-300.
44. Kulldorff M, Fang Z, Walsh SJ. A tree-based scan statistic for database disease surveillance. Biometrics 2003; 59: 323-331.
45. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62: 563-8.
46. Velentgas P, Cole JA, Mo J, Sikes CR, Walker AM. Severe vascular events in migraine patients. Headache 2004; 44: 7.
47. VanDenBrink AM, van den Broek RWM, de Vries R, Bogers AJJC, Avezaat CJJ, Saxena PR. Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000; 55: 1524-30.
48. Petty TL. Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest 2000; 117: S326-31.
49. de Luise C, Lanes SF, Curkendall SM, Jones JK, Lanza L, Sidney S. Cardiovascular morbidity and mortality among person with Chronic Obstructive Pulmonary Disease. Oral presentation at ISPE Annual Conference, August 2004, Bordeaux, France.
50. Tennis P, Cole TB, Annegers JF, Leestma JE, McNutt M, Rajput A. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 1995; 36: 29-36.
51. Derby LE, Tennis P, Jick H. Sudden unexplained death among subjects with refractory epilepsy. Epilepsia 1996; 37: 931-5.
52. Leestma JE, Annegers JF, Brodie MJ, Brown S, Schraeder P, Siscovick D, et al. Sudden unexplained death in epilepsy: observations from a large clinical development program. Epilepsia 1997; 38: 47-55.
53. Jackson G. Erectile Dysfunction and Cardiovascular Disease. IJCP 1999; 53: 363-8.
54. Mann RD. Prescription event monitoring-recent progress and future horizons. Br J Clin Pharmacol 1998; 46: 195-201.
55. Shakir SA. Wilton LV. Boshier A. Layton D. Heeley E. Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. BMJ 2001; 322: 651-2.
56. Boshier A, Wilton LV, Shakir SAW. Evaluation of the safety of sildenafil for male erectile dysfunction: experience gained in general practice use in England in 1999. BJU International 2004; 93: 7.
57. Pfizer, Inc. Pfizer announces early end of European cardiovascular (CV) study: No CV concerns with Viagra. Vienna, Austria: Press Release 2004 (www.pfizer.com).
58. Muller JE, Mittleman A, Maclure M, Sherwood JB, Toffler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study. JAMA 1996; 275: 1405-9.
59. Garcia Rodriguez LA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43: 183-8.
60. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262: 3303-7.
61. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, et al. Risk factors for hip fracture in white women: Study of Osteoporotic Fractures Research Group. N Engl J Med 1995; 332: 767-73.
62. Data on file. Pfizer, Inc., New York, New York.
63. Mills JL, Fradkin J, Schonberger L, Gunn W, Thomson RA, Piper J, et al. Status report on the US Human Growth Hormone Recipient Follow-Up Study. Horm Res 1990; 33: 116-9.
64. Fradkin JE, Schonberger LB, Mills JL, Gunn WJ, Piper JM, Wysowski DK, et al. Creutzfeldt-Jakob Disease in pituitary growth hormone recipients in the United States. JAMA 1991; 265: 880-4.
65. Huillard d'Aignaux J, Alperovitch A, Maccario J. A statistical model to identify the contaminated lots implicated in iatrogenic transmission of Creutzfeldt-Jakob disease among French human growth hormone recipients. Am J Epidemiol 1998; 147: 597-604.
66. Billette de Villemeur T, Deslys JP, Pradel A, Soubrie C, Alperovitch A, Tardieu M, et al. Creutzfeldt-Jakob disease from contaminated growth hormone extracts in France. Neurology 1996; 47: 690-5.
67. Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia, and Creutzfeldt-Jakob disease in patients treated with human pituitary growth hormone in the United Kingdom. BMJ 1991; 302: 824-8.
68. Correll CC, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25.
69. Tucker MA, Meadows AT, Boice JD, Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents in childhood cancer. J Natl Cancer Inst 1987; 78: 459-64.
70. Hawkins MM, Kinnier-Wilson LM, Stovall MA, Marsden HB, Potok MHN, Kingston JE, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ 1992; 304: 951-8.
71. deVathaire F, Francois P, Hill C, Schweisguth O, Rodary C, Sarrazin D, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 1989; 59: 792-6.
72. Tucker MA, D'Angio GJ, Boice JD, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987; 317: 588-93.
73. Glasser DB, Duane K, Lane JM, Healey JH, Caparros-Sison B. The effect of chemotherapy on growth in the skeletally immature individual. Clin Orthop 1991; 262: 93-100.
74. Roman J, Villaizan CJ, Garcia-Foncillas J, Salvador J, Sierrasesumaga L. Growth and growth hormone secretion in children with cancer treated with chemotherapy. J Pediatr 1997; 131: 105-21.
75. Mohnike K, Dorffel W, Timme J, Kluba U, Aumann V, Vorwerk P, et al. Final height and puberty in 40 patients after antileukaemic treatment during childhood. Eur J Pediatr 1997; 156: 272-6.
76. Brennan BM, Rahim A, Adams JA, Eden OB, Shalet SM. Reduced bone mineral density in young adults following cure of acute lymphoblastic leukaemia in childhood. Br J Cancer 1999; 79: 1859-63.
77. Arikoski P, Komulainen J, Voutilainen R, Riikonen P, Parviainen M, Tapanainen P, et al. Reduced bone mineral density in long-term survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1998; 20: 234-40.
78. Bruning PF, Pit JM, deJong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 1990; 61: 308-10.
79. Redman JR, Bajorunas DR, Wong G, McDermott K, Gnecco C, Schneider R, et al. Bone mineralization in women following successful treatment of Hodgkin's disease. Am J Med 1988; 85: 65-72.
80. Holmes SJ, Whitehouse RW, Clark ST, Crowther DC, Adams JE, Shalet SM. Reduced bone mineral density in men following chemotherapy for Hodgkin's disease. Br J Cancer 1994; 70: 371-5.
81. Mastroianni AC, Faden R, Federmen, eds., Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Trials. Washington DC: National Academy of Science Press; 1994.
82. Colley GB, Brantley MD, Larson MK. Family Planning Practices and Pregnancy Intention. Atlanta: CDC; 1997.
83. Herbst AL, Ulfelder H, Poskanzer DC. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971; 284: 878-81.
84. Herbst AL, Kurman RJ, Scully RE, Poskanzer DC. Clear-cell adenocarcinoma of the genital tract in young females. N Engl J Med 1972; 287: 1259-64.
85. Thapa PB, Whitlock JA, Brockman Worrell KG, Gideon P, Mitchel EF Jr, Roberson P, et al. Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years. Cancer 1998; 83: 1461-8.
86. Kinnier-Wilson LM, Kneale GW, Stewart AM. Childhood cancer and pregnancy drugs. Lancet 1981; 2: 314-5.
87. Olsen JH, Hertz H, Blinkenberg K, Verder H. Vitamin K regimens and incidence of childhood cancer in Denmark. BMJ 1994; 308: 895-6.
88. Parker L, Cole M, Craft AW, Hey EN. Neonatal vitamin K administration and childhood cancer in the north of England: retrospective case-control study. BMJ 1998; 316: 189-93.
89. McKinney PA, Juszczak E, Findlay E, Smith K. Case-control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K. BMJ 1998; 316: 173-7.
90. von Kries R, Gobel U, Hachmeister A, Kaletsch U, Michaelis J. Vitamin K and childhood cancer: a population based casecontrol study in Lower Saxony, Germany. BMJ 1996; 313: 199-203.
91. Rosenberg L, Mitchell AA, Parsells JL, et al. Lack of relation of oral clefts to diazepam use during pregnancy. N Engl J Med 1983; 309: 1282-5.
92. Louik C, Mitchell AA, Werler MM, Hanson JW, Shapiro S. Maternal exposure to spermicides in relation to certain birth defects. N Engl J Med 1987; 317: 474-8.
93. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy: I. Oral clefts and cardiac defects. JAMA 1981; 245: 2311-14.
94. Mitchell AA, Schwingl PJ, Rosenberg L, Louik C, Shapiro S. Birth defects in relation to Bendectin use in pregnancy: II. Pyloric stenosis. Am J Obstet Gynecol 1983; 147: 737-42.
95. Covington DL, Tilson H, Elder J, Doi PA, for APR Steering Committee. Assessing teratogenicity of antiretroviral drugs: monitoring and analysis plan of the antiretroviral pregnancy registry. Pharmacoepidemiol Drug Saf 2002; 11: S137.
96. Beghi E, Annegers JF for Collaborative Group for the Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001; 42: 1422-25.
97. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol 2000; 182: 159-63.
98. Shields KE, Galil K, Seward J, et al. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet Gynecol 2001; 98: 14-19.
99. Goldstein DJ, Sundell KL, DeBrota DJ, Offen WW. Determination of pregnancy outcome risk rates after exposure to an intervention. Clinical Pharmacol Ther 2001; 69: 7-13.
100. Food and Drug Administration. Guidance for industry: establishing pregnancy exposure registries. Rockville: FDA; 2002.
101. http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3619t1.rtf/. Accessed February 24, 2004.
102. Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24: 62-9.
103. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv and Ment Disease 2004; 192: 19-27.
104. Curkendall S, Mo Jingping, Glasser DB, Jones J. Cardiovascular disease in patients with schizophrenia, Saskatchewan, Canada. J Clin Psych. 2004; 192: 19-27.
105. Hennessey S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ 2002; 325: 1070-4.
106. Hennessey S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF et al. Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol. Br J Clin Phamacol. 2004; 58: 81-87.
107. http://www.fda.gov/ohrms/dockets/ac/accutane/1782t2a.pdf/. Accessed February 23, 2004.
108. http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3639t1a.pdf/. Accessed February 23, 2004.
109. http://www.fda.gov/ohrms/dockets/ac/00/transcripts/3627t2a. pdf/. Accessed February 23, 2004.
110. http://www.fda.gov/bbs/topics/NEWS/NEW00734.html/. Accessed February 23, 2004.
111. http://www.gsk.com/press_archive/press_06072002.htm/. Accessed February 23, 2004.
112. Smalley W, Shatin S, Wysowski DK. Contraindicated use of cisapride: impact of Food and Drug Administration regulatory action. JAMA 2000; 284: 3036-9.
113. Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. Pharmacoepidemiol Drug Saf 2001; 10: 211-18.
114. http://www.fda.gov/bbs/topics/ANSWERS/ANS00882.html/. Accessed February 23, 2004.
115. http://www.fda.gov/bbs/topics/ANSWERS/ANS00999.html/. Accessed February 23, 2004.
116. http://www.fda.gov/bbs/topics/ANSWERS/ANS01007.html/. Accessed February 23, 2004.
117. Jones JK, Fife D, Curkendall S, Goehring E, Guo JJ, Shannon M. Coprescribing and codispensing of cisapride and contraindicated drugs. JAMA 2001; 286: 1607-9.
118. Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ, et al. The prevalence of prostatism: a populationbased survey of urinary symptoms. J Urol 1993; 150: 85-9.
119. Sagnier PP, Girman CJ, Garraway M, Kumamoto Y, Lieber MM, Richard F, et al. International comparison of the community prevalence of symptoms of prostatism in four countries. Eur Urol 1996; 29: 15-20.
120. Chute CG, Stephenson WP, Guess HA, Lieber M. Benign Prostatic Hyperplasia: a population-based study. Eur Urol 1991; 20: 11-17.
121. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155: 595-600.
122. Roberts RO, Jacobsen SJ, Rhodes T, Girman CJ, Guess HA, Lieber MM. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997; 157: 1711-17.
123. Rhodes T, Girman CJ, Jacobsen SJ, Roberts RO, Guess HA, Lieber MM. Longitudinal prostate growth rates during 5 years in randomly selected community men 40 to 79 years old. J Urol 1999; 161: 1174-9.
124. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, Lieber MM. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158: 481-7.
125. He J, Neal B, Gu D, Suriyawongpaisal P, Xin X, Reynolds R et al. International Collaborative Study of Cardiovascular Disease in Asia (InterASIA): Design and Rationale. Ethn Dis. 2004; 14: 260-268.
126. Dongfeng G, Reynolds K, Wu ZX, Chen J, Duan X, Munter P et al. Prevalence, awareness, treatment, and control of hypertension in China. Hypertension 2002; 40: 920-7.
127. Turner S, Longworth A, Nunn AJ, Choonara I. Unlicensed and off label drug use in paediatric wards: prospective study. BMJ 1998; 316: 343-5.
128. Simons LA, Tett S, Simons J, Lauchlan R, McCallum J, Friedlander Y, Powell I. Multiple medication use in the elderly. Use of prescription and non-prescription drugs in an Australian community setting. Med J Aust 1992; 57: 242-6.
129. Millar WJ. Multiple medication use among seniors. Health Rep. 1998; 9: 11-7.
130. Sclar DA, Robinson LM, Skaer TL, Galin RS. Trends in the prescribing of antidepressant pharmacotherapy: office-based visits, 1990-1995. Clin Ther 1998; 20: 870-84.
131. Martinez M. Agusti A. Arnau JM. Vidal X. Laporte JR. Trends of prescribing patterns for the secondary prevention of myocardial infarction over a 13-year period. Eur J Clin Pharmacol 1998; 54: 203-8.
132. Schmader KE, Hanlon JT, Fillenbaum GG, Huber M, Pieper C, Horner R. Medication use patterns among demented, cognitively impaired and cognitively intact community-dwelling elderly people. Age Ageing 1998; 27: 493-501.
133. Tome MB, Isaac MT. Cost-benefit & cost-effectiveness analysis of the rapid onset of selective serotonin reuptake inhibitors by augmentation. Int J Psychiatry Med 1997; 27: 377-90.
134. Andersson F, Kartman B, Andersson OK. Cost-effectiveness of felodipine-metoprolol (Logimax) and enalapril in the treatment of hypertension. Clin Exp Hypertens 1998; 20: 833-46.
135. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999; 2: 1138-45.
136. Santos R, Cifaldi M, Gregory C, Seitz P. Economic outcomes of a targeted intervention program: the costs of treating allergic rhinitis patients. Am J Man Care 1999; 5: S225-34.
137. Testa MA. Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998; 280: 1490-6.
138. Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol 1999; 49: 541-9.
139. Melfi CA, Croghan TW. Use of claims data for research on treatment and outcomes of depression care. Med Care 1999; 37: AS77-80.
140. Lewis JD, Brensinger C, Bilker WB, Strom BL. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211-18.
141. Metlay JP, Hardy C, Strom BL. Agreement between patient self-report and a Veterans Affairs national pharmacy database for identifying recent exposures to antibiotics. Pharmacoepidemiol Drug Saf 2003; 12: 9-15.
142. Hennessey S, Bilker WB, Weber A, Strom BL. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf 2003; 12: 103-11.
143. Brent RR. The Bendectin saga: another American tragedy. Teratology 1983; 27: 283-6.
144. Brent RL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 1995; 9: 337-49.
145. Holmes LB. Teratogen update: Bendectin. Teratology 1983; 27: 277-81.
146. Neutel CI, Johansen HL. Measuring drug effectiveness by default: the case of Bendectin. Can J Public Health 1995; 86: 66-70.
147. Blumenthal D. Academic-industrial relationships in the life sciences. NEJM 2003; 349: 2452-2459.
148. Zuger A. How tightly do ties between doctor and drug company bind? New York Times July 27, 2004.
149. Steinbrook R. Financial conflicts of interest and the NIH. NEJM 2004; 350: 327-330.
150. International Society for Pharmacoepidemiology (ISPE). 1996. Guidelines for Good Epidemiology Practices for Drug, Device and Vaccine Research in the United States. (http://www.pharmacoepi.org/resources/goodprac.cfm, Accessed August 5, 2004).
151. Ellenberg SS, Fleming TR, DeMets DL. Data Monitoring Committee in Clinical Trials. New York: John Wiley, 2003.
152. Barbone F, McMahon AD, Davey PG, Morris AD, Reid IC, McDevitt DG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet 1998; 352: 1331-6.
153. Hernandez-Diaz S, Hernan MA, Meyer K, Werler MM, Mitchell AA. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epi 2003; 158: 385-91.
154. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epi 2003; 158: 915-20.
155. Califf RM. The need for a national infrastructure to improve the rational use of therapeutics. Pharmacoepidemiol Drug Saf 2002; 11: 319-27.
156. Carr A, Emery SE, Law M, Puls R, Lundgren JD, Powderly WG. An objective case definition of lipodystrophy in HIV-infected adults. Lancet 2003; 361: 726-35.
157. Law M, Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O et al. Modelling the three year risk of myocardial infarction among participants in the DAD study. HIV Med 2003; 4: 1-10.
158. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, Monforte A et al. Cardiovascular risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 1179-93.
159. The DAD Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. NEJM 2003; 349: 1993-2003.
160. Bozzette SA, Ake C, Tam HK, Chang SC, Louis TA. Cardiovascular and cerebrovascular events in patients treated for Human Immunodeficiency Virus infection. NEJM 2003; 348: 702-10.
161. The European Agency for the Evaluation of Medicinal Products. CPMP Public Statement: Metabolic and cardiovascular complications of antiretroviral combination therapy in HIV-infected patients. Doc Ref.: EMEA/CPMP/2383/03. 2003.
162. Johnson JA. Drug target pharmacogenomics: an overview. Am J Pharmacogenomics 2001; 1: 271-81.